Moderna Gains Full BLA Status for Spikevax After FDA Revokes COVID-19 EUA on August 27

The EUA-to-BLA transition for Spikevax (COVID-19 Vaccine, mRNA) is now complete: the FDA revoked Moderna's emergency use authorization on August 27, 2025, confirming that the product manufactured for Moderna US Inc. operates exclusively under full biologics license requirements. For QA directors and regulatory affairs leads, the revocation is not a withdrawal, it is a compliance threshold shift that carries distinct obligations across labeling, post-market surveillance, and GMP conformance.

Under EUA conditions, manufacturers operate against a compressed regulatory framework that permits certain flexibilities not available under a standard BLA. Full approval under 21 CFR Part 601 reinstates the complete post-market commitment schedule, including any required post-approval studies, updated labeling aligned to approved prescribing information, and adherence to ICH Q10 pharmaceutical quality system expectations without EUA carve-outs. Fact sheets for both recipients and healthcare providers were last updated June 25, 2025, signaling that labeling reconciliation was completed ahead of the revocation date.

The regulatory record accompanying the revocation includes a formal Revocation Letter and Revocation Memorandum, both dated August 27, 2025, alongside a Granting Letter issued the same day, a document sequence that reflects a structured transition rather than an abrupt status change. Earlier granting letters from October and November 2023 and a Decision Memorandum from August 2024 trace the iterative authorization history that preceded full approval. Plant heads managing mRNA fill-finish or cold-chain operations tied to this product should confirm that batch release procedures, deviation management, and annual product review cycles now reflect BLA-level expectations rather than EUA-era protocols.

For sterility assurance and process validation leads, the practical read is that any validation packages or comparability protocols submitted under EUA conditions may require reassessment against the approved BLA specifications. Change control submissions going forward will be evaluated under the full supplement pathway, not the more expedited EUA amendment process.

The completeness of Moderna's post-market commitment register, as outlined in the approved BLA, will serve as the near-term compliance benchmark for both internal quality teams and CBER inspectors.

Source: FDA Center for Biologics Evaluation and Research (CBER) via FDA.gov Vaccines, Blood & Biologics RSS Feed, June 9, 2026.